A double-blind, placebo-controlled trial of extracorporeal photopheresis in chronic progressive multiple sclerosis.
Publication/Presentation Date
6-1-1999
Abstract
Extracorporeal photopheresis is a safe therapy for cutaneous T-cell lymphoma and may have efficacy in certain autoimmune disorders. We performed a randomized, double-blinded, placebo-controlled trial of monthly photopheresis therapy in 16 patients with clinically definite multiple sclerosis (MS). All patients had progressed during the preceding year with entry Expanded Disability Status Scale (EDSS) scores between 3.0 and 7.0. Patients received photopheresis or sham therapy for 1 year and were followed for an additional 6 to 12 months. Patients were clinically evaluated by three disability scales: (1) EDSS; (2) Ambulation index and (3) Scripp's quantitative neurologic assessment. No serious side effects occurred in either group. There were no differences between the photopheresis and sham therapy groups by the disability measures. Additionally, there were no differences in progression of MRI plaque burden or evoked potential latencies. In this limited study, photopheresis was found to be safe but did not significantly alter the course of chronic progressive MS.
Volume
5
Issue
3
First Page
198
Last Page
203
ISSN
1352-4585
Published In/Presented At
Rostami, A. M., Sater, R. A., Bird, S. J., Galetta, S., Farber, R. E., Kamoun, M., Silberberg, D. H., Grossman, R. I., & Pfohl, D. (1999). A double-blind, placebo-controlled trial of extracorporeal photopheresis in chronic progressive multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England), 5(3), 198–203. https://doi.org/10.1177/135245859900500310
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
10408721
Department(s)
Administration and Leadership
Document Type
Article